Study finds experimental coagulant risk for heart patients

08/30/2011 | Reuters

The addition of experimental anti-clotting drug darexaban to anti-platelet therapy resulted in a two- to fourfold increase in bleeding among patients with acute coronary syndrome, a Phase II study found. The oral factor Xa inhibitor is undergoing a test for stroke prevention in subjects with atrial fibrillation and previously showed promise in reducing blood-clot risk after orthopedic surgery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA